$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

$eltp Overview Financials Valuation SEC Filings Company Website

2014 Q1 Form 10-K Financial Statement

#000114420414040327 Filed on June 30, 2014

Income Statement

Concept	2014 Q1	2014	2013 Q1
Revenue	$1.028M	$4.601M
YoY Change		35.19%
Cost Of Revenue	$1.046M	$3.236M
YoY Change		39.78%
Gross Profit	-$18.00K	$1.365M
YoY Change		25.44%
Gross Profit Margin	-1.75%	29.67%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development		$3.959M
YoY Change		305.98%
% of Gross Profit		290.0%
Depreciation & Amortization	$120.0K	$453.7K	$90.00K
YoY Change	33.33%	7.18%	-25.0%
% of Gross Profit		33.23%
Operating Expenses	$2.365M	$6.649M
YoY Change		150.76%
Operating Profit	-$2.384M	-$5.284M
YoY Change		238.01%
Interest Expense		$859.3K
YoY Change		238.66%
% of Operating Profit
Other Income/Expense, Net	-$31.65M	-$36.27M
YoY Change		-1444.65%
Pretax Income		-$41.55M
YoY Change		-3763.65%
Income Tax	-$295.0K	-$292.6K
% Of Pretax Income
Net Earnings	-$86.80M	-$41.26M
YoY Change		-2873.04%
Net Earnings / Revenue	-8443.39%	-896.71%
Basic Earnings Per Share	-$0.16	-$0.21
Diluted Earnings Per Share	-$0.16	-$0.21
COMMON SHARES
Basic Shares Outstanding	618.4M shares	463.0M shares
Diluted Shares Outstanding		463.0M shares

Balance Sheet

Concept	2014 Q1	2014	2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.940M	$6.940M	$370.0K
YoY Change	1775.68%	1775.68%	-44.78%
Cash & Equivalents	$6.942M		$369.0K
Short-Term Investments
Other Short-Term Assets	$320.0K	$320.0K	$150.0K
YoY Change	113.33%	113.33%	15.38%
Inventory	$1.932M	$1.930M	$1.358M
Prepaid Expenses
Receivables	$732.1K	$730.0K	$665.2K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$9.925M	$9.920M	$2.543M
YoY Change	290.22%	290.55%	69.56%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.200M	$4.200M	$4.029M
YoY Change	4.24%	4.22%	-5.87%
Goodwill
YoY Change
Intangibles	$6.350M		$694.4K
YoY Change	814.42%		8.02%
Long-Term Investments	$3.350M	$3.350M	$3.340M
YoY Change	0.3%	0.3%	0.0%
Other Assets	$3.843M	$500.0K	$510.0K
YoY Change	653.61%	-1.96%	-5.56%
Total Long-Term Assets	$14.39M	$14.40M	$8.582M
YoY Change	67.72%	67.64%	-2.59%
TOTAL ASSETS
Total Short-Term Assets	$9.925M	$9.920M	$2.543M
Total Long-Term Assets	$14.39M	$14.40M	$8.582M
Total Assets	$24.32M	$24.32M	$11.13M
YoY Change	118.58%	118.51%	7.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.210M	$2.210M	$1.330M
YoY Change	66.17%	66.17%	24.3%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$530.0K	$530.0K	$600.0K
YoY Change	-11.67%
Long-Term Debt Due	$87.57K	$3.400M	$3.390M
YoY Change	-97.42%	-14.79%	-0.29%
Total Short-Term Liabilities	$6.161M	$6.160M	$5.357M
YoY Change	15.0%	14.93%	17.74%
LONG-TERM LIABILITIES
Long-Term Debt	$18.87K	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$131.1K	$99.36M	$91.57K
YoY Change	43.22%	588.09%	-99.56%
Total Long-Term Liabilities	$99.36M	$99.36M	$14.44M
YoY Change	587.99%	588.09%	-30.4%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.161M	$6.160M	$5.357M
Total Long-Term Liabilities	$99.36M	$99.36M	$14.44M
Total Liabilities	$105.5M	$105.5M	$19.80M
YoY Change	432.95%	432.93%	-21.74%
SHAREHOLDERS EQUITY
Retained Earnings	-$225.0M		-$128.4M
YoY Change	75.2%
Common Stock	$144.1M		$120.1M
YoY Change	20.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$306.8K		$306.8K
YoY Change	0.0%
Treasury Stock Shares	100.0K shares		100.0K shares
Shareholders Equity	-$81.20M	-$81.20M	-$8.673M
YoY Change
Total Liabilities & Shareholders Equity	$24.32M	$24.32M	$11.13M
YoY Change	118.58%	118.51%	7.91%

Cashflow Statement

Concept	2014 Q1	2014	2013 Q1
OPERATING ACTIVITIES
Net Income	-$86.80M	-$41.26M
YoY Change		-2873.04%
Depreciation, Depletion And Amortization	$120.0K	$453.7K	$90.00K
YoY Change	33.33%	7.18%	-25.0%
Cash From Operating Activities	-$1.480M	-$4.220M	-$220.0K
YoY Change	572.73%	117.53%	-155.0%
INVESTING ACTIVITIES
Capital Expenditures	-$130.0K	-$510.0K	-$20.00K
YoY Change	550.0%	200.0%	-85.71%
Acquisitions
YoY Change
Other Investing Activities	$60.00K	-$40.00K	$80.00K
YoY Change	-25.0%	100.0%	300.0%
Cash From Investing Activities	-$70.00K	-$560.0K	$60.00K
YoY Change	-216.67%	194.74%	-150.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$10.00M
YoY Change
Debt Paid & Issued, Net		$0.00
YoY Change
Cash From Financing Activities	7.400M	11.35M	480.0K
YoY Change	1441.67%	516.85%	-352.63%
NET CHANGE
Cash From Operating Activities	-1.480M	-4.220M	-220.0K
Cash From Investing Activities	-70.00K	-560.0K	60.00K
Cash From Financing Activities	7.400M	11.35M	480.0K
Net Change In Cash	5.850M	6.570M	320.0K
YoY Change	1728.12%	-2365.52%	255.56%
FREE CASH FLOW
Cash From Operating Activities	-$1.480M	-$4.220M	-$220.0K
Capital Expenditures	-$130.0K	-$510.0K	-$20.00K
Free Cash Flow	-$1.350M	-$3.710M	-$200.0K
YoY Change	575.0%	109.6%	-137.04%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	13333	USD
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	-81198152	USD
CY2013Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11125133	USD
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	24317722	USD
CY2014Q1	us-gaap	Treasury Stock Value TreasuryStockValue	306841	USD
CY2014Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	143555091	USD
CY2013Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-128431375	USD
CY2014Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-225006646	USD
CY2013Q1	us-gaap	Liabilities Current LiabilitiesCurrent	5357255	USD
CY2013Q1	us-gaap	Secured Debt Current SecuredDebtCurrent	3385000	USD
CY2014Q1	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	528750	USD
CY2013Q1	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	600000	USD
CY2014Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	13333	USD
CY2013Q1	us-gaap	Liabilities Liabilities	19798518	USD
CY2014Q1	us-gaap	Liabilities Liabilities	105515874	USD
CY2013Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	14441263	USD
CY2014Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	99355050	USD
CY2014Q1	us-gaap	Common Stock Value CommonStockValue	560244	USD
CY2013Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	119690336	USD
CY2013Q1	us-gaap	Treasury Stock Value TreasuryStockValue	306841	USD
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	6160824	USD
CY2014Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	138890	USD
CY2014Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	131144	USD
CY2014Q1	eltp	Derivative Liability Preferred Shares DerivativeLiabilityPreferredShares	60981570	USD
CY2013	us-gaap	Sales Revenue Net SalesRevenueNet	3403526	USD
CY2013	us-gaap	Cost Of Revenue CostOfRevenue	2315154	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	369023	USD
CY2013Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	665154	USD
CY2013Q1	us-gaap	Inventory Net InventoryNet	1358146	USD
CY2013Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	151051	USD
CY2013Q1	us-gaap	Assets Current AssetsCurrent	2543374	USD
CY2013Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4028943	USD
CY2013Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	694426	USD
CY2013Q1	us-gaap	Cost Method Investments CostMethodInvestments	3329322	USD
CY2013Q1	us-gaap	Security Deposit SecurityDeposit	14314	USD
CY2013Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	267820	USD
CY2013Q1	us-gaap	Deferred Offering Costs DeferredOfferingCosts	246934	USD
CY2013Q1	us-gaap	Assets Assets	11125133	USD
CY2013Q1	eltp	Short Term Loans And Current Portion Of Long Term Debt ShortTermLoansAndCurrentPortionOfLongTermDebt	6296	USD
CY2014Q1	eltp	Derivative Liability Warrants DerivativeLiabilityWarrants	38103446	USD
CY2013Q1	eltp	Derivative Liability Warrants DerivativeLiabilityWarrants	7862848	USD
CY2014	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2013Q1	us-gaap	Common Stock Value CommonStockValue	374495	USD
CY2013Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	152223	USD
CY2013Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1325126	USD
CY2013Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	91571	USD
CY2013Q1	eltp	Derivative Liability Preferred Shares DerivativeLiabilityPreferredShares	6334621	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6941777	USD
CY2014Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	732076	USD
CY2014Q1	us-gaap	Inventory Net InventoryNet	1932486	USD
CY2014Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	318424	USD
CY2014Q1	us-gaap	Assets Current AssetsCurrent	9924763	USD
CY2014Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4199602	USD
CY2014Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	6349922	USD
CY2014Q1	us-gaap	Cost Method Investments CostMethodInvestments	3329322	USD
CY2014Q1	us-gaap	Security Deposit SecurityDeposit	16314	USD
CY2014Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	265043	USD
CY2014Q1	us-gaap	Deferred Offering Costs DeferredOfferingCosts	232756	USD
CY2013Q1	eltp	Assets Noncurrent Excluding Property Plant And Equipment And Intangible Assets AssetsNoncurrentExcludingPropertyPlantAndEquipmentAndIntangibleAssets	3858390	USD
CY2014Q1	eltp	Assets Noncurrent Excluding Property Plant And Equipment And Intangible Assets AssetsNoncurrentExcludingPropertyPlantAndEquipmentAndIntangibleAssets	3843435	USD
CY2014Q1	us-gaap	Assets Assets	24317722	USD
CY2014Q1	us-gaap	Secured Debt Current SecuredDebtCurrent	3385000	USD
CY2014Q1	eltp	Short Term Loans And Current Portion Of Long Term Debt ShortTermLoansAndCurrentPortionOfLongTermDebt	18870	USD
CY2014Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2214871	USD
CY2013Q1	eltp	Preferred Share Derivative Interest Payable PreferredShareDerivativeInterestPayable	27500	USD
CY2014Q1	eltp	Preferred Share Derivative Interest Payable PreferredShareDerivativeInterestPayable	0	USD
CY2013Q1	us-gaap	Stockholders Equity StockholdersEquity	-8673385	USD
CY2014	us-gaap	Contracts Revenue ContractsRevenue	82937	USD
CY2014	us-gaap	Cost Of Revenue CostOfRevenue	3236106	USD
CY2013	us-gaap	Gross Profit GrossProfit	1088372	USD
CY2014	us-gaap	Gross Profit GrossProfit	1365270	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	975250	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3959316	USD
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1513468	USD
CY2014	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2105725	USD
CY2013	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	45866	USD
CY2014	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	82947	USD
CY2013	eltp	Change In Fair Value Of Warrant Derivatives ChangeInFairValueOfWarrantDerivatives	4089491	USD
CY2014	eltp	Change In Fair Value Of Warrant Derivatives ChangeInFairValueOfWarrantDerivatives	-32997869	USD
CY2013	eltp	Change In Fair Value Of Preferred Share Derivatives ChangeInFairValueOfPreferredShareDerivatives	-561684	USD
CY2014	eltp	Change In Fair Value Of Preferred Share Derivatives ChangeInFairValueOfPreferredShareDerivatives	-56518425	USD
CY2013Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2014Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	134083	USD
CY2013Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	93338	USD
CY2014Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	0	USD
CY2013Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5068522	USD
CY2014Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5508377	USD
CY2013Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	USD
CY2013Q1	eltp	Accumulated Amortization Eda Bond Offering Costs AccumulatedAmortizationEdaBondOfferingCosts	107519	USD
CY2014Q1	eltp	Accumulated Amortization Eda Bond Offering Costs AccumulatedAmortizationEdaBondOfferingCosts	121697	USD
CY2013Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	690000000	shares
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	690000000	shares
CY2013Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	374493959	shares
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	560242430	shares
CY2013Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	374393959	shares
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	560142430	shares
CY2013Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	100000	shares
CY2014Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	100000	shares
CY2013	us-gaap	Revenue Other Manufactured Products RevenueOtherManufacturedProducts	2214271	USD
CY2014	us-gaap	Revenue Other Manufactured Products RevenueOtherManufacturedProducts	2982400	USD
CY2013	us-gaap	Contracts Revenue ContractsRevenue	382889	USD
CY2014	us-gaap	Sales Revenue Net SalesRevenueNet	4601376	USD
CY2013	us-gaap	Depreciation And Amortization DepreciationAndAmortization	116921	USD
CY2014	us-gaap	Depreciation And Amortization DepreciationAndAmortization	500906	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	2651505	USD
CY2014	us-gaap	Operating Expenses OperatingExpenses	6648894	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-1563133	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-5283624	USD
CY2013	us-gaap	Interest Expense InterestExpense	253745	USD
CY2014	us-gaap	Interest Expense InterestExpense	859328	USD
CY2013	eltp	Change In Fair Value Of Convertible Note Derivative Instruments ChangeInFairValueOfConvertibleNoteDerivativeInstruments	0	USD
CY2014	eltp	Change In Fair Value Of Convertible Note Derivative Instruments ChangeInFairValueOfConvertibleNoteDerivativeInstruments	-1187879	USD
CY2013	eltp	Interest Expense Preferred Share Derivatives InterestExpensePreferredShareDerivatives	139219	USD
CY2014	eltp	Interest Expense Preferred Share Derivatives InterestExpensePreferredShareDerivatives	40588	USD
CY2013	eltp	Discount In Series E Issuance Attributable To Beneficial Conversion Features DiscountInSeriesEIssuanceAttributableToBeneficialConversionFeatures	437500	USD
CY2014	eltp	Discount In Series E Issuance Attributable To Beneficial Conversion Features DiscountInSeriesEIssuanceAttributableToBeneficialConversionFeatures	0	USD
CY2013	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2014	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	19831	USD
CY2013	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2697343	USD
CY2014	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-91584258	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1134210	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-96867882	USD
CY2013	us-gaap	Income Tax Credits And Adjustments IncomeTaxCreditsAndAdjustments	-353718	USD
CY2014	us-gaap	Income Tax Credits And Adjustments IncomeTaxCreditsAndAdjustments	-292611	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	1487928	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-96575271	USD
CY2013	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2014	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2013	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2013	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	349075642	shares
CY2014	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	463021991	shares
CY2013	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	526880118	shares
CY2014	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	463021991	shares
CY2013Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	774758	USD
CY2014Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	1523341	USD
CY2013Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	676726	USD
CY2014Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	409146	USD
CY2013Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	0	USD
CY2014Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	0	USD
CY2012Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	642848	USD
CY2013	eltp	Finite Lived Intangible Assets Acquired During Period FiniteLivedIntangibleAssetsAcquiredDuringPeriod	51578	USD
CY2014	eltp	Finite Lived Intangible Assets Acquired During Period FiniteLivedIntangibleAssetsAcquiredDuringPeriod	5655495	USD
CY2013	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	USD
CY2014	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	USD
CY2013Q1	eltp	Bond Issue Costs BondIssueCosts	354453	USD
CY2014Q1	eltp	Bond Issue Costs BondIssueCosts	354453	USD
CY2013Q1	eltp	Accumulated Amortization Of Bond AccumulatedAmortizationOfBond	107519	USD
CY2014Q1	eltp	Accumulated Amortization Of Bond AccumulatedAmortizationOfBond	121697	USD
CY2013Q1	eltp	Unamortization Of Bond UnamortizationOfBond	246934	USD
CY2014Q1	eltp	Unamortization Of Bond UnamortizationOfBond	232756	USD
CY2012Q1	us-gaap	Stockholders Equity StockholdersEquity	-14983682	USD
CY2014	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10000000	USD
CY2013	eltp	Stock Issued During Period Value Payment For Preferred Share Derivative Interest StockIssuedDuringPeriodValuePaymentForPreferredShareDerivativeInterest	182684	USD
CY2014	eltp	Stock Issued During Period Value Payment For Preferred Share Derivative Interest StockIssuedDuringPeriodValuePaymentForPreferredShareDerivativeInterest	68089	USD
CY2013	eltp	Conversion Of Series B Series C And Series E Preferred Shares Into Common Shares Value ConversionOfSeriesBSeriesCAndSeriesEPreferredSharesIntoCommonSharesValue	3170671	USD
CY2014	eltp	Conversion Of Series B Series C And Series E Preferred Shares Into Common Shares Value ConversionOfSeriesBSeriesCAndSeriesEPreferredSharesIntoCommonSharesValue	9825066	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	45866	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	82947	USD
CY2013	eltp	Stock Issued During Period Value Payment Of Directors Fees StockIssuedDuringPeriodValuePaymentOfDirectorsFees	96047	USD
CY2014	eltp	Stock Issued During Period Value Payment Of Directors Fees StockIssuedDuringPeriodValuePaymentOfDirectorsFees	110000	USD
CY2013Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	7200	shares
CY2014Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	500	shares
CY2013Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	3175	shares
CY2014Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	104.242	shares
CY2013Q1	eltp	Preferred Stock Conversion Shares PreferredStockConversionShares	83240744	shares
CY2014Q1	eltp	Preferred Stock Conversion Shares PreferredStockConversionShares	148917143	shares
CY2013Q1	eltp	Preferred Stock Closing Price PreferredStockClosingPrice	0.0761
CY2014Q1	eltp	Preferred Stock Closing Price PreferredStockClosingPrice	0.41
CY2013Q1	us-gaap	Derivative Fair Value Of Derivative Liability Amount Not Offset Against Collateral DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral	6334621	USD
CY2014Q1	us-gaap	Derivative Fair Value Of Derivative Liability Amount Not Offset Against Collateral DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral	60981570	USD
CY2013	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	423340	USD
CY2014	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	453746	USD
CY2013	us-gaap	Paid In Kind Interest PaidInKindInterest	182684	USD
CY2014	us-gaap	Paid In Kind Interest PaidInKindInterest	68089	USD
CY2014	eltp	Interest Expense Non Cash InterestExpenseNonCash	568395	USD
CY2013	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	9112	USD
CY2014	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-49439	USD
CY2013	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	1356	USD
CY2014	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	1438	USD
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	268305	USD
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	66922	USD
CY2013	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1053264	USD
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	574340	USD
CY2013	eltp	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	22748	USD
CY2014	eltp	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	169373	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	501611	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	883446	USD
CY2013	eltp	Increase Decrease In Deferred Revenue And Customer Deposits IncreaseDecreaseInDeferredRevenueAndCustomerDeposits	-13335	USD
CY2014	eltp	Increase Decrease In Deferred Revenue And Customer Deposits IncreaseDecreaseInDeferredRevenueAndCustomerDeposits	-13333	USD
CY2013	eltp	Increase Decrease In Derivative Interest Payable Net IncreaseDecreaseInDerivativeInterestPayableNet	-43466	USD
CY2014	eltp	Increase Decrease In Derivative Interest Payable Net IncreaseDecreaseInDerivativeInterestPayableNet	-27500	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1693409	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4216875	USD
CY2013	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	119489	USD
CY2014	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	455323	USD
CY2013	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	33519	USD
CY2014	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	46945	USD
CY2013	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	51578	USD
CY2014	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	58178	USD
CY2013	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-12765	USD
CY2014	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-2777	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-191822	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-557669	USD
CY2013	eltp	Proceeds From Issuance Of Series E Convertible Preferred Stock ProceedsFromIssuanceOfSeriesEConvertiblePreferredStock	437500	USD
CY2014	eltp	Proceeds From Issuance Of Series E Convertible Preferred Stock ProceedsFromIssuanceOfSeriesEConvertiblePreferredStock	0	USD
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10000000	USD
CY2013	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	564500	USD
CY2014	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	868050	USD
CY2013	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	600000	USD
CY2014	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	528750	USD
CY2013	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	6297	USD
CY2014	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	1515	USD
CY2013	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	9856	USD
CY2014	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	47987	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	1585847	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	11347299	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-299384	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	6572754	USD
CY2014	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2013Q3	dei	Entity Public Float EntityPublicFloat	61307116	USD
CY2014	dei	Entity Registrant Name EntityRegistrantName	ELITE PHARMACEUTICALS INC /NV/
CY2014	dei	Entity Central Index Key EntityCentralIndexKey	0001053369
CY2012Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	668407	USD
CY2013	us-gaap	Interest Paid InterestPaid	237874	USD
CY2014	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2014	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2014	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2014	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2014	us-gaap	Interest Paid InterestPaid	289494	USD
CY2013	us-gaap	Income Taxes Paid IncomeTaxesPaid	6099	USD
CY2014	us-gaap	Income Taxes Paid IncomeTaxesPaid	3099	USD
CY2013	eltp	Commitment Shares Issued CommitmentSharesIssued	0	USD
CY2014	eltp	Commitment Shares Issued CommitmentSharesIssued	1112838	USD
CY2013	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	0	USD
CY2014	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	9825066	USD
CY2013	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	0	USD
CY2014	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	5597317	USD
CY2013	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2014	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	600000	USD
CY2014	dei	Document Type DocumentType	10-K
CY2014	dei	Amendment Flag AmendmentFlag	false
CY2014	dei	Document Period End Date DocumentPeriodEndDate	2014-03-31
CY2014	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2014	dei	Trading Symbol TradingSymbol	ELTP
CY2014Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	568042063	shares
CY2014	eltp	Lease Renewal Term LeaseRenewalTerm	P5Y
CY2014	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.9in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><u>NATURE OF BUSINESS</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.9in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Elite Pharmaceuticals, Inc. was incorporated on October 1, 1997 under the laws of the State of Delaware, and its wholly-owned subsidiary Elite Laboratories, Inc. was incorporated on August 23, 1990 under the laws of the State of Delaware. On January 5, 2012, Elite Pharmaceuticals was reincorporated under the laws of the State of Nevada. Elite Labs engages primarily in researching, developing and licensing proprietary controlled-release drug delivery systems and products. The Company is also equipped to manufacture controlled-release products on a contract basis for third parties and itself if and when the products are approved; however the Company has concentrated on developing orally administered controlled-release products. These products include drugs that cover therapeutic areas for pain, allergy and infection. The Company also engages in research and development activities for the purpose of obtaining Food and Drug Administration approval, and, thereafter, commercially exploiting generic and new controlled-release pharmaceutical products. The Company also engages in contract research and development on behalf of other pharmaceutical companies.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q1	us-gaap	Area Of Land AreaOfLand	15000	sqft
CY2014	eltp	Lease Initiation Date LeaseInitiationDate	2010-07-01
CY2014	eltp	Lease Term LeaseTerm	5 years and 6 months
CY2014	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 66pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><u>CONCENTRATION OF CREDIT RISK</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 66pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company maintains cash balances, which, at times, may exceed the amounts insured by the Federal Deposit Insurance Corp. Uninsured balances at March 31, 2014 are $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6,941,777</font>. Management does not believe that there is any significant risk of losses.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 66pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: rgb(152,72,6); font-size-adjust: none; font-stretch: normal" align="justify"><b> </b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 66pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company in the normal course of business extends credit to its customers based on contract terms and performs ongoing credit evaluations. An allowance for doubtful accounts due to uncertainty of collection is established based on historical collection experience. Amounts are written off when payment is not received after exhaustive collection efforts. During Fiscal 2014 and Fiscal 2013 the Company generated all its revenues from ten and six companies, respectively. The termination of the contracts with either of such companies will result in the loss of a significant amount of revenues currently being earned.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 66pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><u>USE OF ESTIMATES</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 66pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, the recognition of revenue, the amount of the allowance for doubtful accounts receivable and the fair value of intangible assets, stock-based awards and derivatives.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q1	us-gaap	Inventory Gross InventoryGross	1932487	USD
CY2013	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	2475	shares
CY2014	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	3175	shares
CY2013	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	29863556	shares
CY2014	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	91796043	shares
CY2014Q1	eltp	Lease Termination Cost Payable LeaseTerminationCostPayable	50000	USD
CY2014Q1	us-gaap	Deferred Revenue DeferredRevenue	152223	USD
CY2014Q1	us-gaap	Advance Rent AdvanceRent	200000	USD
CY2013	us-gaap	Stock Issued During Period Shares Issued For Cash StockIssuedDuringPeriodSharesIssuedForCash	358663	shares
CY2014Q1	us-gaap	Cash Uninsured Amount CashUninsuredAmount	6941777	USD
CY2014	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0in"></td> <td style="TEXT-ALIGN: left; WIDTH: 63.6pt"> <div><b>NOTE 27</b></div> </td> <td style="TEXT-ALIGN: justify"> <div><b>CONTINGENCIES</b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 63pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">On March 1, 2013, the Company did not renew its Directors and Officers insurance policy and the Company did not have a Directors and Officers insurance policy since that date. As of the date of filing this Annual Report on Form 10-K, management has not been notified any claims against the Company.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 63pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 63pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">During Fiscal 2014, as part of the Company’s efforts to ensure the retention and continuity of key employees, officers and directors in the event of a change of control of the ownership of the Company, the Board of Directors passed a resolution whereby, in the event of a change in control of the ownership of the Company, key executives would receive an amount equal to twelve months of such executive’s salary, and certain Directors and managers would receive an amount equal to six months of such Director’s or managers fees or salaries, as applicable. In addition, the resolution passed provided for the immediate vesting of outstanding options, in the event of a change of control.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2013Q1	us-gaap	Inventory Gross InventoryGross	1451484	USD
CY2013Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9097463	USD
CY2014Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9707979	USD
CY2013	eltp	Derivative Liability Conversion Of Convertible Securities Change In Value DerivativeLiabilityConversionOfConvertibleSecuritiesChangeInValue	626696	USD
CY2014	eltp	Derivative Liability Conversion Of Convertible Securities Change In Value DerivativeLiabilityConversionOfConvertibleSecuritiesChangeInValue	3237937	USD
CY2013	eltp	Adjustments To Additional Paid In Capital Conversion Of Convertible Securities AdjustmentsToAdditionalPaidInCapitalConversionOfConvertibleSecurities	3140807	USD
CY2014	eltp	Adjustments To Additional Paid In Capital Conversion Of Convertible Securities AdjustmentsToAdditionalPaidInCapitalConversionOfConvertibleSecurities	9733270	USD
CY2012Q1	eltp	Warrants Outstanding WarrantsOutstanding	161478979	shares
CY2013Q1	eltp	Warrants Outstanding WarrantsOutstanding	139344939	shares
CY2013	eltp	Warrants Issued During Period WarrantsIssuedDuringPeriod	0	shares
CY2014	eltp	Warrants Issued During Period WarrantsIssuedDuringPeriod	0	shares
CY2013	eltp	Warrant Exercised Forfeitures And Expirations During Period WarrantExercisedForfeituresAndExpirationsDuringPeriod	22134040	shares
CY2014	eltp	Warrant Exercised Forfeitures And Expirations During Period WarrantExercisedForfeituresAndExpirationsDuringPeriod	37201848	shares
CY2014Q1	eltp	Warrants Outstanding WarrantsOutstanding	102143091	shares
CY2012Q1	eltp	Warrants Outstanding Weighted Average Exercise Price WarrantsOutstandingWeightedAverageExercisePrice	0.09
CY2013Q1	eltp	Warrants Outstanding Weighted Average Exercise Price WarrantsOutstandingWeightedAverageExercisePrice	0.08
CY2013	eltp	Warrants Issued During Period Weighted Average Exercise Price WarrantsIssuedDuringPeriodWeightedAverageExercisePrice	0.06
CY2014	eltp	Warrants Issued During Period Weighted Average Exercise Price WarrantsIssuedDuringPeriodWeightedAverageExercisePrice	0
CY2013	eltp	Warrant Exercised Forfeitures And Expirations During Period Weighted Average Exercise Price WarrantExercisedForfeituresAndExpirationsDuringPeriodWeightedAverageExercisePrice	0.20
CY2014	eltp	Warrant Exercised Forfeitures And Expirations During Period Weighted Average Exercise Price WarrantExercisedForfeituresAndExpirationsDuringPeriodWeightedAverageExercisePrice	0.09
CY2014Q1	eltp	Warrants Outstanding Weighted Average Exercise Price WarrantsOutstandingWeightedAverageExercisePrice	0.06
CY2012Q1	eltp	Derivative Liability Warrants DerivativeLiabilityWarrants	11987222	USD
CY2013	eltp	Derivative Liability Warrants Issued In Period DerivativeLiabilityWarrantsIssuedInPeriod	0	USD
CY2014	eltp	Derivative Liability Warrants Issued In Period DerivativeLiabilityWarrantsIssuedInPeriod	0	USD
CY2013	eltp	Derivative Liability Warrants Exercised In Period DerivativeLiabilityWarrantsExercisedInPeriod	707216	USD
CY2014	eltp	Derivative Liability Warrants Exercised In Period DerivativeLiabilityWarrantsExercisedInPeriod	8392452	USD
CY2013	eltp	Derivative Liability Warrants Change In Fair Value Of Warrant Liability DerivativeLiabilityWarrantsChangeInFairValueOfWarrantLiability	-3417158	USD
CY2014	eltp	Derivative Liability Warrants Change In Fair Value Of Warrant Liability DerivativeLiabilityWarrantsChangeInFairValueOfWarrantLiability	33527473	USD
CY2014	us-gaap	Debt Instrument Convertible Number Of Equity Instruments DebtInstrumentConvertibleNumberOfEquityInstruments	14286	pure
CY2014	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	1000	USD
CY2014Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	1110000	USD
CY2014Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	210000	USD
CY2014Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	220000	USD
CY2014Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	85000	USD
CY2013	eltp	Reversal Of Change In Fair Value Of Preferred Share Derivatives ReversalOfChangeInFairValueOfPreferredShareDerivatives	-4089491	USD
CY2013	eltp	Reversal Of Interest Expense Preferred Share Derivatives ReversalOfInterestExpensePreferredShareDerivatives	139219	USD
CY2013	eltp	Series E Preferred Stock Shares Issued During Period SeriesEPreferredStockSharesIssuedDuringPeriod	437.5	shares
CY2014	eltp	Series E Preferred Stock Shares Issued During Period SeriesEPreferredStockSharesIssuedDuringPeriod	0	shares
CY2013	eltp	Detachable Warrants Issued During Period DetachableWarrantsIssuedDuringPeriod	0	shares
CY2014	eltp	Detachable Warrants Issued During Period DetachableWarrantsIssuedDuringPeriod	0	shares
CY2013	eltp	Proceeds From Issuance Of Series E Convertible Preferred Stock And Warrants Gross ProceedsFromIssuanceOfSeriesEConvertiblePreferredStockAndWarrantsGross	437500	USD
CY2014	eltp	Proceeds From Issuance Of Series E Convertible Preferred Stock And Warrants Gross ProceedsFromIssuanceOfSeriesEConvertiblePreferredStockAndWarrantsGross	0	USD
CY2013	eltp	Valuation Of Warrants Issued Gross ValuationOfWarrantsIssuedGross	0	USD
CY2014	eltp	Valuation Of Warrants Issued Gross ValuationOfWarrantsIssuedGross	0	USD
CY2013	eltp	Valuation Of Beneficial Conversion Gross ValuationOfBeneficialConversionGross	437500	USD
CY2014	eltp	Valuation Of Beneficial Conversion Gross ValuationOfBeneficialConversionGross	0	USD
CY2013	eltp	Proceeds From Issuance Of Detachable Warrants ProceedsFromIssuanceOfDetachableWarrants	0	USD
CY2014	eltp	Proceeds From Issuance Of Detachable Warrants ProceedsFromIssuanceOfDetachableWarrants	0	USD
CY2013	eltp	Proceeds From Beneficial Conversion Feature ProceedsFromBeneficialConversionFeature	437500	USD
CY2014	eltp	Proceeds From Beneficial Conversion Feature ProceedsFromBeneficialConversionFeature	0	USD
CY2013	eltp	Proceeds From Issuance Of Series E Convertible Preferred Stock And Warrants ProceedsFromIssuanceOfSeriesEConvertiblePreferredStockAndWarrants	437500	USD
CY2014	eltp	Proceeds From Issuance Of Series E Convertible Preferred Stock And Warrants ProceedsFromIssuanceOfSeriesEConvertiblePreferredStockAndWarrants	0	USD
CY2014	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	10000000	USD
CY2014Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.07
CY2014Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	90000	USD
CY2014Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	1670000	USD
CY2014Q1	us-gaap	Secured Debt SecuredDebt	3385000	USD
CY2013Q1	us-gaap	Secured Debt SecuredDebt	3385000	USD
CY2013Q1	us-gaap	Secured Long Term Debt SecuredLongTermDebt	0	USD
CY2014Q1	us-gaap	Secured Long Term Debt SecuredLongTermDebt	0	USD
CY2013	eltp	Stock Issued During Period Value Payment Of Employee Salaries StockIssuedDuringPeriodValuePaymentOfEmployeeSalaries	50072	USD
CY2014	eltp	Stock Issued During Period Value Payment Of Employee Salaries StockIssuedDuringPeriodValuePaymentOfEmployeeSalaries	368233	USD
CY2014	eltp	Incremental Common Shares Attributable To Stock Options IncrementalCommonSharesAttributableToStockOptions	174359	shares
CY2014	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	148917143	shares
CY2014	eltp	Incremental Common Shares Attributable To Warrant IncrementalCommonSharesAttributableToWarrant	15782718	shares
CY2013	eltp	Reversal Of Change In Fair Value Of Warrant Derivatives ReversalOfChangeInFairValueOfWarrantDerivatives	561.684	USD
CY2013	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1900660	USD
CY2013	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	83240744	shares
CY2013	eltp	Incremental Common Shares Attributable To Stock Options IncrementalCommonSharesAttributableToStockOptions	141919	shares
CY2013	eltp	Incremental Common Shares Attributable To Warrant IncrementalCommonSharesAttributableToWarrant	94421813	shares
CY2012Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2999000	shares
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3939000	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	985000	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3000000	shares
CY2013	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2014	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	308333	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	-45000	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	1195000	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5435667	shares
CY2012Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.53
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.18
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.12
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.07
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.08
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	1.59
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	1.60
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.54
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	9389684	shares
CY2013	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	465181	USD
CY2014	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	69512	USD
CY2013	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	31354	USD
CY2014	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	30835	USD
CY2013	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	362347	USD
CY2014	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	29668	USD
CY2010	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.10
CY2014Q1	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	85344	USD
CY2014Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	65196	USD
CY2014	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2015-12-31
CY2013	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2014	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2014	eltp	Operating Lease Description OperatingLeaseDescription	5 years with 2 tenant renewal options for 5 years each
CY2013	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2014	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2013	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	6099	USD
CY2014	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	3099	USD
CY2013	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2014	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		USD
CY2013	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	90338	USD
CY2014	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	33820	USD
CY2013	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	-359817	USD
CY2014	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	-295710	USD
CY2014Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	150540	USD
CY2014	us-gaap	Valuation Allowance Commentary ValuationAllowanceCommentary	At March 31, 2014 and 2013, a 100% valuation allowance is provided
CY2013	eltp	Actual Lease Payments ActualLeasePayments	81228	USD
CY2014	eltp	Actual Lease Payments ActualLeasePayments	83259	USD
CY2013Q1	us-gaap	Deferred Rent Credit DeferredRentCredit	68263	USD
CY2014Q1	us-gaap	Deferred Rent Credit DeferredRentCredit	18824	USD
CY2013	eltp	Stock Issued During Period Value Execution Of Warrants StockIssuedDuringPeriodValueExecutionOfWarrants	599384	USD
CY2014	eltp	Stock Issued During Period Value Execution Of Warrants StockIssuedDuringPeriodValueExecutionOfWarrants	3601020	USD
CY2013	eltp	Adjustments To Additional Paid In Capital Proceeds Received In Exchange For Beneficial Conversion Provisions Embedded In Series E Preferred Shares AdjustmentsToAdditionalPaidInCapitalProceedsReceivedInExchangeForBeneficialConversionProvisionsEmbeddedInSeriesEPreferredShares	437500	USD
CY2012	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	130000	USD
CY2013	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	110000	USD
CY2014Q1	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	27500	USD
CY2012	us-gaap	Officers Compensation OfficersCompensation	67917	USD
CY2013	us-gaap	Officers Compensation OfficersCompensation	368233	USD
CY2014Q1	us-gaap	Officers Compensation OfficersCompensation	198481	USD
CY2013	us-gaap	Officers Compensation OfficersCompensation	50072	USD
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1000000	shares
CY2014Q1	eltp	Lease Termination Costs Current LeaseTerminationCostsCurrent	0	USD
CY2010	eltp	Sharebased Compensation Arrangements By Sharebased Payment Award Options Grants In Period Grant Date Fair Value SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue	93452	USD
CY2013	eltp	Sharebased Compensation Arrangements By Sharebased Payment Award Options Grants In Period Grant Date Fair Value SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue	113842	USD
CY2014	eltp	Sharebased Compensation Arrangements By Sharebased Payment Award Options Grants In Period Grant Date Fair Value SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue	202497	USD
CY2013Q1	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	6295	USD
CY2014Q1	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	0	USD
CY2013Q1	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	0	USD
CY2014Q1	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	0	USD
CY2013	us-gaap	License And Services Revenue LicenseAndServicesRevenue	806365	USD
CY2014	us-gaap	License And Services Revenue LicenseAndServicesRevenue	1536039	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	146119	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	478233	USD
CY2014	eltp	Stock Option Plan Expense1 StockOptionPlanExpense1	18836	USD
CY2013	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2014	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	7953591	USD
CY2014	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	107960	USD
CY2014	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	18836	USD
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	24300	USD
CY2013	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	0	USD
CY2013	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	USD
CY2013	eltp	Stock Issued During Period Value Issued For Capital Purchase Agreement StockIssuedDuringPeriodValueIssuedForCapitalPurchaseAgreement	240144	USD
CY2014	eltp	Stock Issued During Period Value Issued For Capital Purchase Agreement StockIssuedDuringPeriodValueIssuedForCapitalPurchaseAgreement	-47987	USD
CY2013Q1	eltp	Equipment Financing Payable Current EquipmentFinancingPayableCurrent	0	USD
CY2014Q1	eltp	Equipment Financing Payable Current EquipmentFinancingPayableCurrent	18870	USD
CY2013Q1	eltp	Equipment Financing Payable Non Current EquipmentFinancingPayableNonCurrent	0	USD
CY2014Q1	eltp	Equipment Financing Payable Non Current EquipmentFinancingPayableNonCurrent	87574	USD
CY2013Q1	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent		USD
CY2014Q1	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent		USD
CY2013Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	68260	USD
CY2014Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	18821	USD
CY2013Q1	eltp	Lease Termination Costs Current LeaseTerminationCostsCurrent	0	USD
CY2014Q1	eltp	Lease Termination Costs Non Current LeaseTerminationCostsNonCurrent	24749	USD
CY2013Q1	eltp	Lease Termination Costs Non Current LeaseTerminationCostsNonCurrent	23311	USD
CY2014	eltp	Financing Lease Term FinancingLeaseTerm	P60M
CY2014Q1	eltp	Financing Lease Interest Rate FinancingLeaseInterestRate	0.068	pure
CY2014	eltp	Financing Lease Expiration Date1 FinancingLeaseExpirationDate1	2019-02-28
CY2014	eltp	Straight Line Deferred Rent Liability Adjustments StraightLineDeferredRentLiabilityAdjustments	-56518	USD
CY2013	eltp	Straight Line Deferred Rent Liability Adjustments StraightLineDeferredRentLiabilityAdjustments	0	USD
CY2014	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2013	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2014Q1	eltp	Accumulated Amortization Of Impaired Assets AccumulatedAmortizationOfImpairedAssets	0	USD
CY2013Q1	eltp	Accumulated Amortization Of Impaired Assets AccumulatedAmortizationOfImpairedAssets	0	USD
CY2014	us-gaap	Property Plant And Equipment Depreciation Methods PropertyPlantAndEquipmentDepreciationMethods	straight-line method
CY2014	us-gaap	Finite Lived Intangible Assets Amortization Method FiniteLivedIntangibleAssetsAmortizationMethod	straight-line method

Files In Submission

Name	View Source	Status
0001144204-14-040327-index-headers.html	Edgar Link	pending
0001144204-14-040327-index.html	Edgar Link	pending
0001144204-14-040327.txt	Edgar Link	pending
0001144204-14-040327-xbrl.zip	Edgar Link	pending
eltp-20140331.xml	Edgar Link	completed
eltp-20140331.xsd	Edgar Link	pending
eltp-20140331_cal.xml	Edgar Link	unprocessable
eltp-20140331_def.xml	Edgar Link	unprocessable
eltp-20140331_lab.xml	Edgar Link	unprocessable
eltp-20140331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v381997_10k.htm	Edgar Link	pending
v381997_ex21.htm	Edgar Link	pending
v381997_ex23.htm	Edgar Link	pending
v381997_ex31-1.htm	Edgar Link	pending
v381997_ex31-2.htm	Edgar Link	pending
v381997_ex32-1.htm	Edgar Link	pending
v381997_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2014 Q1 Form 10-K Financial Statement

#000114420414040327 Filed on June 30, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2014 Q1 Form 10-K Financial Statement

#000114420414040327 Filed on June 30, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp